RecruitingNot ApplicableNCT06646653

Feasibility Clinical Study of the Alma System in Treating Primary Postpartum Hemorrhage


Sponsor

ResQ Medical Ltd

Enrollment

10 participants

Start Date

Apr 14, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Feasibility clinical study of the Alma System in treating primary postpartum hemorrhage (PPH).


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria4

  • Adult Female, 18 years of age or older at time of consent.
  • Subject or her legally authorized representative is able to understand and provide consent to participate in the clinical investigation.
  • Subjects who present with an atonic uterus for at least 10 minutes after expulsion of placenta with failure to obtain contraction and/or Subjects who have lost blood post-vaginal delivery \> = 500 ml and lost blood post-cesarian delivery \> = 1000 ml and according to the Investigator's judgment, require an intervention.
  • Failed first-line intervention of uterotonics and uterine massage/bimanual uterine massage to stop bleeding.

Exclusion Criteria18

  • Subjects who do not provide informed consent to participate in the clinical investigation.
  • Subjects who deliver at a uterus size \< 34 weeks.
  • Subjects who have lost \> 1000 ml of blood for vaginal birth and \> 2000 ml for caesarian delivery.
  • Subjects who have abnormal PT, PTT and INR.
  • Subjects who present with retained placenta, uterine lacerations, or for any other conditions outside of atonic post-partum hemorrhage.
  • PPH that the investigator determines to require more aggressive treatment, including any of the following:
  • Hysterectomy;
  • B-lynch suture;
  • Uterine artery embolization or ligation;
  • Hypogastric ligation;
  • Known uterine anomaly;
  • Ongoing intrauterine pregnancy.
  • Placental abnormality including any of the following:
  • Known placenta accreta;
  • Retained placenta with known risk factors for placenta accreta (e.g., history of prior uterine surgery, including prior c-section and placenta previa);
  • Retained placenta without easy manual removal.
  • Known uterine rupture
  • Unresolved uterine inversion.

Interventions

DEVICEAlma System

Subjects diagnosed with postpartum hemorrhage will receive the Alma System. This system comprises a soft silicone cylindrical device placed within the uterus. Gentle suction is applied, prompting the uterus to contract and reduce in size. This contraction compresses the blood vessels, halting the bleeding.


Locations(1)

University Clinical Hospital of Mostar

Mostar, Bosnia and Herzegovina

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06646653